首页> 美国卫生研究院文献>BMC Medicine >Acute kidney injury biomarkers: renal angina and the need for a renal troponin I
【2h】

Acute kidney injury biomarkers: renal angina and the need for a renal troponin I

机译:急性肾损伤的生物标志物:肾绞痛和肾钙蛋白I的需要

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acute kidney injury (AKI) in hospitalized patients is independently associated with increased morbidity and mortality in pediatric and adult populations. Continued reliance on serum creatinine and urine output to diagnose AKI has resulted in our inability to provide successful therapeutic and supportive interventions to prevent and mitigate AKI and its effects. Research efforts over the last decade have focused on the discovery and validation of novel urinary biomarkers to detect AKI prior to a change in kidney function and to aid in the differential diagnosis of AKI. The aim of this article is to review the AKI biomarker literature with a focus on the context in which they should serve to add to the clinical context facing physicians caring for patients with, or at-risk for, AKI. The optimal and appropriate utilization of AKI biomarkers will only be realized by understanding their characteristics and placing reasonable expectations on their performance in the clinical arena.
机译:住院患者的急性肾损伤(AKI)与儿童和成人人群的发病率和死亡率增加独立相关。持续依赖血清肌酐和尿量来诊断AKI导致我们无法提供成功的治疗和支持性干预措施来预防和减轻AKI及其影响。过去十年的研究工作集中在发现和验证新型尿液生物标志物上,以在肾功能改变之前检测AKI并帮助AKI的鉴别诊断。本文的目的是回顾AKI生物标志物文献,重点是在应该为照顾AKI或处于AKI风险中的医生所面临的临床环境中增加的背景。仅通过了解AKI生物标记物的特性并对其在临床上的表现提出合理的期望,才能实现AKI生物标记物的最佳和适当利用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号